scPharmaceuticals Inc. Reports Second Quarter 2025 Financial Results and Provides Business Update
scPharmaceuticals (NASDAQ:SCPH) reported strong Q2 2025 financial results, with FUROSCIX庐 generating $16 million in net revenue, representing a 99% increase year-over-year. The company achieved significant growth with 20,200 FUROSCIX doses filled, up 117% from Q2 2024.
Key highlights include the successful launch of FUROSCIX for chronic kidney disease (CKD) treatment in April 2025, and the upcoming sNDA submission for the 80mg/1mL FUROSCIX Autoinjector in Q3 2025, which aims to reduce treatment time from five hours to under ten seconds. The company maintained a strong financial position with $40.8 million in cash as of June 30, 2025.
Despite revenue growth, the company reported a net loss of $18.0 million for Q2 2025, compared to $17.1 million in Q2 2024, with increased operating expenses across R&D and SG&A.
scPharmaceuticals (NASDAQ:SCPH) ha riportato risultati finanziari solidi per il secondo trimestre del 2025, con FUROSCIX庐 che ha generato 16 milioni di dollari di ricavi netti, segnando un aumento del 99% rispetto all'anno precedente. L'azienda ha registrato una crescita significativa con 20.200 dosi di FUROSCIX somministrate, in aumento del 117% rispetto al secondo trimestre 2024.
Tra i punti salienti vi 猫 il lancio riuscito di FUROSCIX per il trattamento della malattia renale cronica (CKD) nell'aprile 2025 e la prossima presentazione della sNDA per il FUROSCIX Autoiniettore 80mg/1mL nel terzo trimestre 2025, che mira a ridurre il tempo di trattamento da cinque ore a meno di dieci secondi. L'azienda ha mantenuto una solida posizione finanziaria con 40,8 milioni di dollari in liquidit脿 al 30 giugno 2025.
Nonostante la crescita dei ricavi, la societ脿 ha registrato una perdita netta di 18,0 milioni di dollari nel secondo trimestre 2025, rispetto ai 17,1 milioni del secondo trimestre 2024, a causa dell'aumento delle spese operative in R&S e SG&A.
scPharmaceuticals (NASDAQ:SCPH) report贸 s贸lidos resultados financieros en el segundo trimestre de 2025, con FUROSCIX庐 generando 16 millones de d贸lares en ingresos netos, lo que representa un aumento del 99% interanual. La compa帽铆a logr贸 un crecimiento significativo con 20,200 dosis de FUROSCIX dispensadas, un incremento del 117% respecto al segundo trimestre de 2024.
Los aspectos destacados incluyen el exitoso lanzamiento de FUROSCIX para el tratamiento de la enfermedad renal cr贸nica (ERC) en abril de 2025 y la pr贸xima presentaci贸n de la sNDA para el autoinyector FUROSCIX de 80mg/1mL en el tercer trimestre de 2025, que busca reducir el tiempo de tratamiento de cinco horas a menos de diez segundos. La compa帽铆a mantuvo una s贸lida posici贸n financiera con 40,8 millones de d贸lares en efectivo al 30 de junio de 2025.
A pesar del crecimiento en ingresos, la empresa report贸 una p茅rdida neta de 18,0 millones de d贸lares en el segundo trimestre de 2025, en comparaci贸n con 17,1 millones en el segundo trimestre de 2024, debido al aumento de gastos operativos en I+D y SG&A.
scPharmaceuticals (NASDAQ:SCPH)電� 2025雲� 2攵勱赴 臧曤牓頃� 鞛 鞁れ爜鞚� 氤搓碃頄堨溂氅�, FUROSCIX庐臧� 1,600毵� 雼煬鞚� 靾滊Г於滌潉 旮半頃� 鞝勲厔 霃欔赴 雽�牍� 99% 歃濌皜頄堨姷雼堧嫟. 須岇偓電� 20,200須� FUROSCIX 韴棳搿� 2024雲� 2攵勱赴 雽�牍� 117% 靹膘灔頃橂姅 靹标臣毳� 雰堨姷雼堧嫟.
欤检殧 靹标臣搿滊姅 2025雲� 4鞗� 毵岇劚 鞁犾灔 歆堩櫂(CKD) 旃橂鞖� FUROSCIX鞚� 靹标车鞝侅澑 於滌嫓鞕� 2025雲� 3攵勱赴鞐� 鞝滌稖 鞓堨爼鞚� 80mg/1mL FUROSCIX 鞛愲彊欤检瀰旮� sNDA臧� 鞛堨姷雼堧嫟. 鞚� 鞛愲彊欤检瀰旮半姅 旃橂 鞁滉皠鞚� 5鞁滉皠鞐愳劀 10齑� 氙鸽鞙茧 雼稌頃橂姅 瓴冹潉 氇╉憸搿� 頃╇媹雼�. 須岇偓電� 2025雲� 6鞗� 30鞚� 旮办 4,080毵� 雼煬鞚� 順勱笀鞚� 氤挫湢頃橂┌ 韮勴儎頃� 鞛 靸來儨毳� 鞙犾頄堨姷雼堧嫟.
毵れ稖 靹膘灔鞚� 鞛堨棃歆�毵�, 須岇偓電� 2025雲� 2攵勱赴 1,800毵� 雼煬鞚� 靾滌啇鞁�鞚� 旮半頄堨溂氅�, 鞚措姅 2024雲� 2攵勱赴鞚� 1,710毵� 雼煬 靻愳嫟氤措嫟 歃濌皜頃� 靾橃箻搿�, 鞐瓣惮臧滊皽 氚� 韺愲Г甏�毽箘 歃濌皜鞐� 霐半ジ 瓴瓣臣鞛呺媹雼�.
scPharmaceuticals (NASDAQ:SCPH) a annonc茅 de solides r茅sultats financiers pour le deuxi猫me trimestre 2025, avec FUROSCIX庐 g茅n茅rant 16 millions de dollars de revenus nets, soit une augmentation de 99 % par rapport 脿 l'ann茅e pr茅c茅dente. L'entreprise a connu une croissance significative avec 20 200 doses de FUROSCIX distribu茅es, soit une hausse de 117 % par rapport au deuxi猫me trimestre 2024.
Les points cl茅s incluent le lancement r茅ussi de FUROSCIX pour le traitement de la maladie r茅nale chronique (MRC) en avril 2025, ainsi que la prochaine soumission de la sNDA pour le st茅rilet FUROSCIX 80 mg/1 mL au troisi猫me trimestre 2025, visant 脿 r茅duire le temps de traitement de cinq heures 脿 moins de dix secondes. L'entreprise a maintenu une solide position financi猫re avec 40,8 millions de dollars en liquidit茅s au 30 juin 2025.
Malgr茅 la croissance des revenus, la soci茅t茅 a enregistr茅 une perte nette de 18,0 millions de dollars au deuxi猫me trimestre 2025, contre 17,1 millions au deuxi猫me trimestre 2024, en raison de l'augmentation des d茅penses op茅rationnelles li茅es 脿 la R&D et aux SG&A.
scPharmaceuticals (NASDAQ:SCPH) meldete starke Finanzergebnisse f眉r das zweite Quartal 2025, wobei FUROSCIX庐 einen Nettoumsatz von 16 Millionen US-Dollar erzielte, was einem Anstieg von 99 % im Jahresvergleich entspricht. Das Unternehmen verzeichnete ein erhebliches Wachstum mit 20.200 abgef眉llten FUROSCIX-Dosen, ein Plus von 117 % gegen眉ber dem zweiten Quartal 2024.
Zu den wichtigsten Highlights z盲hlen die erfolgreiche Markteinf眉hrung von FUROSCIX zur Behandlung der chronischen Nierenerkrankung (CKD) im April 2025 sowie die bevorstehende Einreichung der sNDA f眉r den 80mg/1mL FUROSCIX Autoinjektor im dritten Quartal 2025, der die Behandlungszeit von f眉nf Stunden auf unter zehn Sekunden reduzieren soll. Das Unternehmen behielt mit 40,8 Millionen US-Dollar an liquiden Mitteln zum 30. Juni 2025 eine starke finanzielle Position bei.
Trotz des Umsatzwachstums meldete das Unternehmen f眉r das zweite Quartal 2025 einen Nettoverlust von 18,0 Millionen US-Dollar, verglichen mit 17,1 Millionen US-Dollar im zweiten Quartal 2024, bedingt durch gestiegene Betriebsausgaben in Forschung & Entwicklung sowie Vertrieb und Verwaltung.
- FUROSCIX revenue grew 99% year-over-year to $16 million in Q2 2025
- Doses shipped increased 117% year-over-year to 20,200 units
- Successfully expanded into CKD market with April 2025 launch
- Sales to Integrated Delivery Networks increased 70% quarter-over-quarter
- Approximately 4,700 unique prescribers have prescribed FUROSCIX to date
- Strong cash position of $40.8 million as of June 30, 2025
- Net loss increased to $18.0 million from $17.1 million year-over-year
- Gross-to-net discount increased to 27% from 23% in Q1 2025
- SG&A expenses increased to $21.2 million from $17.5 million year-over-year
- R&D expenses rose to $4.1 million from $2.7 million year-over-year
Insights
FUROSCIX shows explosive 99% YoY revenue growth with strong commercial execution and expanding market opportunities.
scPharmaceuticals delivered an impressive Q2 with
Particularly noteworthy is the company's expanded market penetration, with sales to Integrated Delivery Networks increasing
From a profitability perspective, the gross-to-net discount increased to
Operating expenses increased significantly, with R&D expenses rising to
With
Generated net FUROSCIX庐 revenue of
Doses shipped to patients increased
Launch of FUROSCIX in chronic kidney disease
Autoinjector remains on track for sNDA submission in Q3 2025; designed to reduce treatment time from five hours to less than ten seconds
Cash and cash equivalents of
Investor conference call and webcast today, Thursday, August 7th, at 4:30pm ET
BURLINGTON, Mass., Aug. 07, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (the 鈥淐ompany鈥�), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient-centric innovations, today reported financial results for the second quarter ended June 30, 2025, and provided a business update.
鈥淲e鈥檙e very pleased with the continued momentum behind FUROSCIX, with net revenue of
鈥淲e are encouraged that the Ambulatory Specialty Model (ASM), aimed at improving the upstream management of heart failure, was proposed in the 2026 Physician Fee Schedule by the Centers for Medicare and Medicaid Services on July 14, 2025. The ASM will test whether adjusting Medicare Part B payments for cardiologists based on their performance on targeted quality measures results in enhanced quality of care and reduced costs. By shifting accountability from the hospital to the clinical specialist for all unplanned heart failure hospitalizations, not just 30-day readmissions, with a specific reference to early intervention for worsening symptoms, we believe that this new ASM program has the potential to be a tailwind to the already successful uptake for FUROSCIX.鈥�
Business Update
- For the second quarter ended June 30, 2025, scPharmaceuticals reports:
- Net FUROSCIX revenue of
$16.0 million , compared to$8.1 million for the second quarter of 2024, representing approximately99% annual growth - Approximately 20,200 FUROSCIX doses filled compared to approximately 9,300 doses filled in the second quarter of 2024, representing approximately
117% annual growth - Sales to Integrated Delivery Networks increased
70% in the second quarter of 2025 compared to the first quarter of 2025 - Gross-to-net (GTN) discount of
27% for the second quarter of 2025 compared to23% for the first quarter of 2025 - Approximately 4,700 unique prescribers have prescribed FUROSCIX from launch through the end of the second quarter of 2025
- Net FUROSCIX revenue of
- FUROSCIX CKD Indication Expansion Launch: In late April 2025, scPharmaceuticals formally launched FUROSCIX for the treatment of edema in patients with CKD, and prescriptions are currently being written by nephrologists in the expanded indication.
- 80mg/1mL FUROSCIX Autoinjector: the SCP-111 program, which is designed to reduce administration time from five hours to less than ten seconds, is on track for a targeted sNDA filing in the current quarter.
Second Quarter 2025 Financial Results
Product revenues were听
Research and development expenses were听
Selling, general and administrative expenses were听
scPharmaceuticals reported a net loss of听
As of听June 30, 2025, scPharmaceuticals鈥� total shares outstanding was 53,290,227.
Conference Call and Webcast Information
scPharmaceuticals鈥� management will host a conference call and webcast to review the Company鈥檚 second quarter 2025 results today, Thursday, August 7, at 4:30 p.m. ET.
A link to the live webcast can be found .
Participants should dial (800) 715-9871 (toll-free) or (646) 307-1963 (toll) and use the passcode 4965353.
The live webcast and replay of the conference call can be accessed or under 鈥淣ews & Events鈥� in the Investor Relations section of the Company鈥檚 website, .
INDICATION
FUROSCIX庐 (furosemide injection), 80 mg/10 mL for subcutaneous use is indicated for the treatment of edema (i.e., congestion, fluid overload, or hypervolemia) in adult patients with chronic heart failure or chronic kidney disease (CKD), including the nephrotic syndrome.
IMPORTANT SAFETY INFORMATION
FUROSCIX is contraindicated in patients with anuria and in patients with a history of hypersensitivity to furosemide, any component of the FUROSCIX formulation, or medical adhesives.
Furosemide may cause fluid, electrolyte, and metabolic abnormalities, particularly in patients receiving higher doses, patients with inadequate oral electrolyte intake, and in elderly patients. Serum electrolytes, CO2, BUN, creatinine, glucose, and uric acid should be monitored frequently during furosemide therapy.
Excessive diuresis may cause dehydration and blood volume reduction with circulatory collapse and possibly vascular thrombosis and embolism, particularly in elderly patients.
Furosemide can cause dehydration and azotemia. If increasing azotemia and oliguria occur during treatment of severe progressive renal disease, discontinue furosemide.
Cases of tinnitus and reversible or irreversible hearing impairment and deafness have been reported with furosemide. Reports usually indicate that furosemide ototoxicity is associated with rapid injection, severe renal impairment, the use of higher than recommended doses, hypoproteinemia or concomitant therapy with aminoglycoside antibiotics, ethacrynic acid, or other ototoxic drugs.
In patients with severe symptoms of urinary retention (because of bladder emptying disorders, prostatic hyperplasia, urethral narrowing), the administration of furosemide can cause acute urinary retention related to increased production and retention of urine. These patients require careful monitoring, especially during the initial stages of treatment.
Contact with water or other fluids and certain patient movements during treatment may cause the On-body Infusor to prematurely terminate infusion. Ensure patients can detect and respond to alarms.
The most common adverse reactions with FUROSCIX administration in clinical trials were site and skin reactions including erythema, bruising, edema, and injection site pain.
Please see the full () and ()
About scPharmaceuticals
At scPharmaceuticals, we are powered by passion, driven by patient care. Our mission is focused on advancing cardiorenal care through innovative, integrated treatments that address unmet patient needs.
Our goal is to become the foremost advocate for patient-centric cardiorenal care, driving global health improvements through specialized, multidisciplinary approaches. scPharmaceuticals is expanding its reach, offering integrated therapies and products that address diverse healthcare needs and potentially improve the lives of our patients. scPharmaceuticals is headquartered in听Burlington, MA.听For more information, please visit听.
Forward-Looking Statements
This press release contains 鈥渇orward-looking statements鈥� within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, but not limited to, statements regarding the development and commercialization of products, such as the Autoinjector, and its potential to increase patient care and the treatment of fluid at home; the anticipated submission of a sNDA for 80mg/1mL FUROSCIX Autoinjector in the third quarter of 2025; our commercial strategy for FUROSCIX and anticipated sales; the impact of our ongoing expansion efforts; the impact of ASM program; our participation in upcoming events and presentations; and the timing of any of the foregoing. Any forward-looking statements in this press release are based on management鈥檚 current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include but are not limited to, our dependence on the commercial success of FUROSCIX and, if approved, our other product candidates; risks related to the receipt of regulatory approval for our product candidates; risks related to our ability to manufacture, or the ability of third parties to deliver, sufficient product for commercialization of FUROSCIX or any of our product candidates, if approved; risks related to our history of operating losses, we have a history of significant operating losses and expect to incur significant and increasing losses for the foreseeable future; we may never achieve or maintain profitability; we may need additional funding and may be unable to raise capital when needed, which would force us to delay, reduce or eliminate our product development programs or commercialization efforts; the terms of our credit facility and revenue participation financing facility place restrictions on our operating and financial flexibility, and we may not have cash available to us in an amount sufficient to enable us to make interest or principal payments on our indebtedness when due; clinical and preclinical development involves a lengthy and expensive process with an uncertain outcome, and any difficulties or delays in the commencement or completion, or the termination or the potential for the results from any clinical trials to support submission of sNDAs or comparable regulatory applications; and the risk that global economic factors and uncertainties will impact the Company鈥檚 operations. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the sections entitled 鈥淩isk Factors鈥� in the Company鈥檚 Annual Report on Form 10-K for the year ended听December 31, 2024, on file with the听Securities and Exchange Commission, available at the Securities and Exchange Commission鈥檚 website at听, as well as discussions of potential risks, uncertainties and other important factors in the Company鈥檚 subsequent filings with the听Securities and Exchange Commission. All information in this press release is as of the date of the release, and the Company undertakes no duty to update this information unless required by law.
Katherine Miranda
scPharmaceuticals Inc., 781-301-6869
[email protected]
Investors:
Matthew Beck
astr partners, (917) 415-1750
[email protected]
| scPharmaceuticals Inc. | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | ||||||||
| Unaudited Consolidated Statements of Operations | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | ||||||||
| (in thousands, except share and per share data) | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | ||||||||
| 听 | THREE MONTHS ENDED JUNE 30, | 听 | SIX MONTHS ENDED JUNE 30, | 听 | ||||||||||||
| 听 | 听 | 2024 | 听 | 听 | 听 | 2025 | 听 | 听 | 听 | 2024 | 听 | 听 | 听 | 2025 | 听 | 听 |
| 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | ||||||||
| Product revenues, net | $ | 8,054 | 听 | 听 | $ | 16,041 | 听 | 听 | $ | 14,156 | 听 | 听 | $ | 27,793 | 听 | 听 |
| 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | ||||||||
| Operating expenses: | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | ||||||||
| Cost of product revenues | 听 | 2,300 | 听 | 听 | 听 | 5,011 | 听 | 听 | 听 | 4,085 | 听 | 听 | 听 | 8,482 | 听 | 听 |
| Research and development | 听 | 2,677 | 听 | 听 | 听 | 4,098 | 听 | 听 | 听 | 5,403 | 听 | 听 | 听 | 8,729 | 听 | 听 |
| Selling, general and administrative | 听 | 17,508 | 听 | 听 | 听 | 21,226 | 听 | 听 | 听 | 34,955 | 听 | 听 | 听 | 42,633 | 听 | 听 |
| Total operating expenses | 听 | 22,485 | 听 | 听 | 听 | 30,335 | 听 | 听 | 听 | 44,443 | 听 | 听 | 听 | 59,844 | 听 | 听 |
| Loss from operations | 听 | (14,431 | ) | 听 | 听 | (14,294 | ) | 听 | 听 | (30,287 | ) | 听 | 听 | (32,051 | ) | 听 |
| Change in fair value of term loan | 听 | - | 听 | 听 | 听 | (150 | ) | 听 | 听 | - | 听 | 听 | 听 | 150 | 听 | 听 |
| Change in fair value of revenue purchase and sale liability | 听 | - | 听 | 听 | 听 | (2,560 | ) | 听 | 听 | - | 听 | 听 | 听 | (4,312 | ) | 听 |
| Other (expense) income | 听 | (1,189 | ) | 听 | 听 | (128 | ) | 听 | 听 | 1,783 | 听 | 听 | 听 | 8 | 听 | 听 |
| Interest income | 听 | 664 | 听 | 听 | 听 | 509 | 听 | 听 | 听 | 1,541 | 听 | 听 | 听 | 1,225 | 听 | 听 |
| Interest expense | 听 | (2,134 | ) | 听 | 听 | (1,401 | ) | 听 | 听 | (4,235 | ) | 听 | 听 | (2,786 | ) | 听 |
| Net loss | $ | (17,090 | ) | 听 | $ | (18,024 | ) | 听 | $ | (31,198 | ) | 听 | $ | (37,766 | ) | 听 |
| Net loss per share, basic and diluted | $ | (0.44 | ) | 听 | $ | (0.34 | ) | 听 | $ | (0.80 | ) | 听 | $ | (0.70 | ) | 听 |
| Weighted鈥攁verage common shares outstanding, basic and diluted | 听 | 38,984,745 | 听 | 听 | 听 | 53,719,662 | 听 | 听 | 听 | 38,968,438 | 听 | 听 | 听 | 53,698,138 | 听 | 听 |
| 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | ||||||||
| scPharmaceuticals Inc. | 听 | 听 | 听 | 听 | 听 | ||||
| Unaudited Consolidated Balance Sheet Data | 听 | 听 | 听 | 听 | 听 | ||||
| (in thousands) | 听 | DECEMBER 31, | 听 | JUNE 30, | 听 | ||||
| 听 | 听 | 听 | 2024 | 听 | 听 | 听 | 2025 | 听 | 听 |
| Cash and cash equivalents | 听 | $ | 75,655 | 听 | 听 | $ | 40,809 | 听 | 听 |
| Working capital | 听 | 听 | 90,973 | 听 | 听 | 听 | 58,299 | 听 | 听 |
| Total assets | 听 | 听 | 107,519 | 听 | 听 | 听 | 80,255 | 听 | 听 |
| Term loan | 听 | 听 | 51,350 | 听 | 听 | 听 | 51,200 | 听 | 听 |
| Revenue purchase and sale liability | 听 | 听 | 26,869 | 听 | 听 | 听 | 28,957 | 听 | 听 |
| Accumulated deficit | 听 | 听 | (366,494 | ) | 听 | 听 | (404,260 | ) | 听 |
| Total stockholders鈥� equity (deficit) | 听 | 听 | 13,320 | 听 | 听 | 听 | (21,316 | ) | 听 |
| 听 | |||||||||
FAQ
What was scPharmaceuticals (SCPH) revenue for Q2 2025?
How many FUROSCIX doses did SCPH ship in Q2 2025?
What is the status of SCPH's FUROSCIX Autoinjector development?
How much cash does scPharmaceuticals have as of Q2 2025?
When did SCPH launch FUROSCIX for chronic kidney disease (CKD)?
